Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells

International Journal of Molecular Medicine

Volumn 37, Issue 3, 2016, Pages 690-702

  Hu, Jun ^a,c   Wang, Junjie ^b   Wang, Gang ^b   Yao, Zhongjun ^c   Dang, Xiaoqian ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SHANGHAI EIGHTH PEOPLE'S HOSPITAL   (China)

^c HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Drug delivery; DSPEPEG2000 polymeric liposome; Glioma; Multidrug resistance; Quercetin; Temozolomide

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]; LACTATE DEHYDROGENASE; LIPOSOME; MACROGOL 2000; QUERCETIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC AGENT; DACARBAZINE; MACROGOL DERIVATIVE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG RELEASE; GLIOMA; HEART; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; KIDNEY; LIVER; LUNG; NONHUMAN; PARTICLE SIZE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SPLEEN; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PROCEDURES; RANDOMIZATION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; LIPOSOMES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; QUERCETIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84959185586     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2458     Document Type: Article

References (53)

1. Allen TM and Cullis PR: Drug delivery systems: entering the mainstream. Science 303: 1818-1822, 2004.
2. Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR and Farokhzad OC: Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 8: 1063-1070, 2008.
3. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS and Farokhzad OC: Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83: 761-769, 2008.
4. Ji JL, Huang XF and Zhu HL: Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med Chem 12: 210-218, 2012.
5. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S and O'Regan RM: Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 7: 657-667, 2006.
6. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD and Redemann C: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464, 1991.
7. Gabizon A and Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 (Suppl 4): 15-21, 1997.
8. Haran G, Cohen R, Bar LK and Barenholz Y: Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151: 201-215, 1993.
9. Gang W, Jie WJ, Ping ZL, Ming S, Ying LJ, Lei W and Fang Y: Liposomal quercetin: evaluating drug delivery in vitro and biodistribution in vivo. Expert Opin Drug Deliv 9: 599-613, 2012.
10. Wang G, Wang J, Luo J, Wang L, Chen X, Zhang L and Jiang S: PEG2000-DPSE-coated quercetin nanoparticles remarkably enhanced anticancer effects through induced programed cell death on C6 glioma cells. J Biomed Mater Res A 101: 3076-3085, 2013.
11. Xavier CP, Lima CF, Rohde M and Pereira-Wilson C: Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol 68: 1449-1457, 2011.
12. Siegelin MD, Reuss DE, Habel A, Rami A and von Deimling A: Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro-oncol 11: 122-131, 2009.
13. Kim EJ, Choi CH, Park JY, Kang SK and Kim YK: Underlying mechanism of quercetin-induced cell death in human glioma cells. Neurochem Res 33: 971-979, 2008.
14. Heijnen CG, Haenen GR, van Acker FA, van der Vijgh WJ and Bast A: Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups. Toxicol In Vitro 15: 3-6, 2001.
15. Ong CS, Tran E, Nguyen TT, Ong CK, Lee SK, Lee JJ, Ng CP, Leong C and Huynh H: Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol Rep 11: 727-733, 2004.
16. Gupta K and Panda D: Perturbation of microtubule polymerization by quercetin through tubulin binding: a novel mechanism of its antiproliferative activity. Biochemistry 41: 13029-13038, 2002.
17. Wang IK, Lin-Shiau SY and Lin JK: Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 35: 1517-1525, 1999.
18. Jakubowicz-Gil J, Langner E and Rzeski W: Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. Pharmacol Rep 63: 403-416, 2011.
19. Yang CY, Tsay SY and Tsiang RC: Encapsulating aspirin into a surfactant-free ethyl cellulose microsphere using non-toxic solvents by emulsion solvent-evaporation technique. J Microencapsul 18: 223-236, 2001.
20. Saha S, Reddy ChV, Xu S, Sankar S, Neamati N and Patro B: Synthesis and SAR studies of marine natural products ma'edamines A, B and their analogues. Bioorg Med Chem Lett 23: 5135-5139, 2013.
21. Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, et al: Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J Med Chem 55: 9492-9509, 2012.
22. Xu S, Oshima T, Imada T, Masuda M, Debnath B, Grande F, Garofalo A and Neamati N: Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Lett 335: 421-430, 2013.
23. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA and Neamati N: Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci USA 109: 16348-16353, 2012.
24. Yamada R, Kostova MB, Anchoori RK, Xu S, Neamati N and Khan SR: Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Cancer Biol Ther 9: 192-203, 2010.
25. Xu S, Grande F, Garofalo A and Neamati N: Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther 12: 937-949, 2013.
26. Thirant C, Gavard J, Junier MP and Chneiweiss H: Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies. Proteomics Clin Appl 7: 79-90, 2013.
27. Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H and Oku N: T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm 392: 218-223, 2010.
28. Ishida T, Atobe K, Wang X and Kiwada H: Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release 115: 251-258, 2006.
29. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, Yuki K, Tanaka K, Takenaga M, Igarashi R, et al: Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res 26: 2270-2279, 2009.
30. Liu Y and Lu W: Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv 9: 671-686, 2012.
31. Lin X, Gao R, Zhang Y, Qi N, Zhang Y, Zhang K, He H and Tang X: Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. Expert Opin Drug Deliv 9: 767-781, 2012.
32. Fang JY and Al-Suwayeh SA: Nanoparticles as delivery carriers for anticancer prodrugs. Expert Opin Drug Deliv 9: 657-669, 2012.
33. Battaglia L and Gallarate M: Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 9: 497-508, 2012.
34. Hofheinz RD, Gnad-Vogt SU, Beyer U and Hochhaus A: Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16: 691-707, 2005.
35. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, et al: Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 122: 253-266, 2012.
36. Russo M, Spagnuolo C, Tedesco I, Bilotto S and Russo GL: The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol 83: 6-15, 2012.
37. Boots AW, Balk JM, Bast A and Haenen GR: The reversibility of the glutathionyl-quercetin adduct spreads oxidized quercetin induced toxicity. Biochem Biophys Res Commun 338: 923-929, 2005.
38. Boots AW, Li H, Schins RP, Duffin R, Heemskerk JW, Bast A and Haenen GR: the quercetin paradox. Toxicol Appl Pharmacol 222: 89-96, 2007.
39. Ferraresi R, Troiano L, Roat E, Lugli E, Nemes E, Nasi M, Pinti M, Fernandez MI, Cooper EL and Cossarizza A: Essential requirement of reduced glutathione (GSH) for the anti-oxidant effect of the flavonoid quercetin. Free Radic Res 39: 1249-1258, 2005.
40. Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, Hong YK and Joe YA: The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 360: 195-204, 2015.
41. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al: p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455: 1129-1133, 2008.
42. Lino MM and Merlo A: PI3Kinase signaling in glioblastoma. J Neurooncol 103: 417-427, 2011.
43. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, et al: Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 3: ra81, 2010.
44. Ahmed F and Discher DE: Self-porating polymersomes of PEG-PLA and PEG-PCL: Hydrolysis-triggered controlled release vesicles. J Control Release 96: 37-53, 2004.
45. Cai S, Vijayan K, Cheng D, Lima EM and Discher DE: Micelles of different morphologies-advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery. Pharm Res 24: 2099-2109, 2007.
46. Ahmed F, Pakunlu RI, Srinivas G, Brannan A, Bates F, Klein ML, Minko T and Discher DE: Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol Pharm 3: 340-350, 2006.
47. Kumar N, Ravikumar MN and Domb AJ: Biodegradable block copolymers. Adv Drug Deliv Rev 53: 23-44, 2001.
48. Shive MS and Anderson JM: Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28: 5-24, 1997.
49. Siepmann J and Göpferich A: Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 48: 229-247, 2001.
50. Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS and Ting G: Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Anticancer Res 29: 2111-2120, 2009.
51. Lee JS, Ankone M, Pieters E, Schiffelers RM, Hennink WE and Feijen J: Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes. J Control Release 155: 282-288, 2011.
52. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH and Boerman OC: Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292: 1071-1079, 2000.
53. Ishida T, Ichikawa T, Ichihara M, Sadzuka Y and Kiwada H: Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Control Release 95: 403-412, 2004.